Cumberland Pharmaceuticals Inc. (CPIX) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company. The reporting period is defined by a major strategic shift: the company completed a transaction on July 1, 2026, to sell its portfolio of FDA-approved commercial brands to Apotex Inc. for $100 million in cash. Consequently, the company has transitioned from a commercial-stage entity to a clinical-stage development company focused on its proprietary pipeline, primarily the thromboxane antagonist ifetroban, and its majority-owned subsidiary, Cumberland Emerging Technologies (CET).
Key Financial Metrics
Revenue and Profitability (Six Months Ended June 30, 2026):
- Net Revenues (Continuing Operations): $330,308 (down from $547,425 in the prior year).
- Net Revenues (Discontinued Operations): $17,602,251 (revenues from sold brands).
- Net Loss (Continuing Operations): $(5,962,447).
- Net Loss (Discontinued Operations): $(1,599,034).
- Total Net Loss: $(7,561,481) compared to a net income of $512,977 in the prior year.
- Operating Expenses: Total costs and expenses for continuing operations were $6,423,139, consisting primarily of General and Administrative ($4.87M) and Research and Development ($1.54M).
Liquidity and Balance Sheet (As of June 30, 2026):
- Cash and Cash Equivalents: $3,862,402 (down from $11,444,693 at year-end 2025).
- Total Assets: $62,879,694 (down from $76,823,992).
- Total Liabilities: $45,773,246.
- Shareholders' Equity: $17,438,013.
- Debt: The revolving line of credit was repaid in full ($5.24M) on June 29, 2026. No long-term debt remained as of June 30, 2026.
- Working Capital: Negative $1.55 million overall; negative $11.8 million for continuing operations due to the classification of inventory as discontinued operations while related payables remained in continuing operations.
Material Changes vs. Prior Period
- Strategic Divestiture: The most significant change is the classification of the commercial branded product business (Talicia, Sancuso, Vibativ, etc.) as Discontinued Operations. This resulted in a shift from product revenue generation to a pure R&D model.
- Revenue Decline: Continuing operations revenue dropped significantly as the company no longer sells commercial products. The $17.6M in revenue from discontinued operations represents the final sales prior to the July 1 closing.
- Debt Elimination: The company utilized cash to fully repay its $5.2 million revolving credit facility with Pinnacle Bank in late June 2026, removing all debt obligations prior to the Apotex transaction closing.
- Cash Flow: Net cash used in financing activities was $6.15 million, primarily driven by the debt repayment. Operating cash flow from continuing operations was negative $3.5 million, offset by positive cash flow from discontinued operations.
Guidance, Outlook, and Subsequent Events
Subsequent Events (Post-June 30, 2026):
- Transaction Closing: On July 1, 2026, the company received $100 million in cash from Apotex. It is also entitled to up to $9 million in inventory reimbursement over the following 12 months.
- Special Dividend: On July 13, 2026, the Board declared a special cash dividend of $1.50 per share, totaling approximately $22.5 million, paid on July 31, 2026.
- Share Repurchase: The Board authorized a new open-market share repurchase program of up to $5 million, replacing the previous program.
Outlook and Risks:
- Pipeline Focus: Future success depends entirely on the clinical development of ifetroban for Duchenne Muscular Dystrophy (DMD), Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis prevention.
- Liquidity: Management believes the $100 million proceeds, plus interest income and the inventory reimbursement, are sufficient to fund operations for at least the next 12 months.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the inability to generate future product revenue if trials fail, and the need to manage capital efficiently in a development-stage environment.
Investor Verification Checklist
- Transaction Finality: Verify the final closing adjustments and the exact amount of the $100 million Apotex proceeds received, including any post-closing inventory reimbursements.
- Cash Runway: Confirm the post-dividend cash balance and the projected burn rate for the ifetroban clinical programs to validate the 12-month liquidity assertion.
- Discontinued Operations Accounting: Review the specific allocation of assets and liabilities between continuing and discontinued operations to ensure the negative working capital in continuing operations is purely a classification issue and not a liquidity crisis.
- Clinical Milestones: Monitor upcoming data readouts for the FIGHT DMD study and the cancer metastasis prevention study, as these are the primary value drivers for the restructured company.
- Share Repurchase Activity: Track the execution of the new $5 million share repurchase program to assess management's confidence in the stock price and capital allocation strategy.